[Disclosure] Alteogen(196170) Signs Exclusive License Agreement with GSK Subsidiary for ALT-B4 Valued up to KRW 420.0B

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2026-01-20

Disclosure Type: Major Management Matters Related to Investment Decisions (Execution of Exclusive License Agreement for Human Hyaluronidase Product (ALT-B4))

💡 3-Second Summary

Alteogen has entered into an exclusive license agreement with a U.S. subsidiary of global pharmaceutical company GSK to develop and commercialize a subcutaneous (SC) formulation of GSK’s anticancer therapy using its ALT-B4 technology. Under this agreement, Alteogen will receive a non-refundable upfront payment of approximately KRW 29.5B, with total potential milestone payments reaching up to KRW 420.0B, plus separate sales royalties.

📊 1. [Key Disclosure Content & Summary of Major Figures]

This disclosure pertains to the tech-export of Alteogen’s proprietary Hybrozyme platform-based human hyaluronidase (ALT-B4) to a global pharmaceutical firm. All KRW figures are translated based on the Seoul Foreign Exchange Brokerage closing rate on January 20, 2026 (1,473.60 KRW/USD).

• Contract Party: Tesaro, Inc. (A U.S.-based subsidiary of GSK plc)
  • The parent company GSK reported a revenue of approximately KRW 62.0T (￡31,376M) in the fiscal year 2024.
• Scope of Agreement: Exclusive license for the development and commercialization of a subcutaneous (SC) formulation of GSK’s anticancer therapy, dostarlimab, applying Alteogen’s ALT-B4.
• Contract Amount Breakdown (Non-refundable):
  • Upfront Payment: USD 20,000,000 (Approx. KRW 29.5B)
    • Equivalent to approx. 28.7% of Alteogen’s 2024 consolidated annual revenue (KRW 102.9B). Expected to be received within 10 business days from the contract date (by February 3, 2026).
  • Milestones: Up to USD 265,000,000 (Approx. KRW 390.5B)
    • To be received upon the successful achievement of each specified milestone in clinical trials, regulatory approvals, and commercialization phases.
  • Total Contract Value: Up to USD 285,000,000 (Approx. KRW 420.0B) (※ Sales royalties are separate)
  • Sales Royalties: A specified percentage of net sales after the first commercial sale of the product applying ALT-B4.
• Contract Period: Until the expiration of the royalty period.
• Nondisclosure & Deferred Disclosure: Specific details of milestones and royalties are withheld from disclosure until the termination of the contract due to confidentiality agreements.

📈 2. [Expert View: What This Disclosure Means for Investors]

• Impact on Financial Fundamental & Profitability: The non-refundable upfront payment of KRW 29.5B represents a substantial portion (28.7%) of the previous year’s revenue, which could positively impact near-term cash flow and the financial fundamental. Securing a contract with a subsidiary of a global big pharma may enhance the market validation and credibility of the company’s technology.
• Structural Risks & Volatility: This contract is a conditional agreement that depends on regulatory approvals. Due to the inherent nature of biotech licensing agreements, the total milestone payments may be downsized or reduced depending on the outcomes of clinical trials or failure to secure regulatory approvals.
• Termination Risks: The contract may be terminated prematurely due to regulatory halts in research, failure in regulatory approvals, or the convenience/insolvency of the counterparty. Investors should monitor the progress of clinical milestones carefully rather than treating the maximum potential payout as a guaranteed future fact.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s selection as a formulation partner for GSK’s anticancer drug serves as an important validation of its platform technology. The influx of a non-refundable upfront payment exceeding 28% of last year’s revenue is undoubtedly positive. However, when evaluating biotech licensing disclosures, investors should avoid focusing solely on the ‘maximum headline value.’ The remaining KRW 390.5B in milestones represents conditional payments that can only be unlocked by navigating complex clinical and regulatory hurdles. As noted in the contract’s risk factors, the possibility of termination remains if clinical trials stall. Tracking the long-term development timeline with a balanced approach remains crucial. This commentary outlines objective metrics and does not constitute any buy or sell signals.

📢 Disclaimer & Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.